Clinical Trial · NCT05398302

Radiologically Guided Biopsies of Metastatic Castration Resistant Prostate Cancer to Identify Mechanisms of Resistance in Patients Undergoing 177Lu-PSMA Radioligand Therapy

Overview

This clinical trial studies mechanisms of resistance to 177-lutetium prostate specific membrane antigen (177Lu-PSMA) radioligand therapy using image-guided biopsies in patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). Diagnostic procedures, such as image guided biopsies, may help in learning how well 177Lu-PSMA works to kill tumor cells and allow doctors to plan better treatment.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

Phase 1

Contacts

Rejah Marie Nabong (Clinical Trials Program Manager)

rmalano@mednet.ucla.edu

310-206-7372

ClinicalTrials.gov

NCT05398302

Drug / Compound

177Lu-PSMA

Isotope(s):

Target(s):

PSMA

Eligibility

Inclusion

Evidence of lymph node or soft tissue metastatic disease amenable to image-guided biopsy
Histologically confirmed prostate cancer
Eligible for 177Lu-PSMA-617 under expanded access protocol (IRB# 21-5010) or as part of an approved trial

Exclusion

Patients with significant congenital or acquired bleeding disorders

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…